Search

Paige Arnold, a graduate student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), is one of 13 PhD candidates selected from around the world to receive a Harold M. Weintraub Graduate Student Award for the quality, originality, and significance of their doctoral research.

… Wednesday, March 2, 2022 Paige Arnold , a graduate student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), is one of 13 PhD candidates selected from around the world to receive a Harold M. Weintraub Graduate Student Award for the quality, originality, and significance of

A new drug could be an effective treatment for some people with low-grade glioma.

… Wednesday, August 7, 2024 Brain tumors are among the deadliest and most difficult cancers to treat. But the US Food and Drug Administration (FDA) has now approved a new drug that slows the growth of low-grade diffuse gliomas with a certain gene mutation.  “This represents the first new treatment option

By deciphering the biology of T cells, MSK scientists gave immunotherapy a boost.

… Wednesday, December 28, 2016 Immunologists are fond of car analogies. The T cells that protect us from infections and cancer, they say, have an ignition switch. They also have gas pedals and brakes. How immunologists, like good molecular mechanics, deciphered what makes T cells hum is a story that reaches

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.

… Monday, June 5, 2017 A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD , Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer

MSK introduced its first new creative campaign in nearly two decades. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York.

… Tuesday, September 2, 2014 Memorial Sloan Kettering Cancer Center today introduced its first new creative campaign in nearly two decades: More Science. Less Fear. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York. MSK

Four summer students -- Jeannie Camarillo, Emily Grzybowski, Nathaniel Kim, and Daniel Triner -- were named 2010 Rubin and Sarah Shaps Scholars.

… Thursday, September 1, 2011 Four summer students are named Rubin and Sarah Shaps Scholars each summer. Students are selected on the basis of their outstanding undergraduate credentials and their performance in our summer program. Jeannie Camarillo, a junior majoring in physiology at the University of

MSK physicians and scientists are involved in notable research to be presented at the meeting and are available to comment on a variety of topics within leukemia, lymphoma, and multiple myeloma.

… Friday, December 4, 2020 Thousands of oncology experts from around the world will tune in December 5-8, 2020 for The American Society of Hematology’s (ASH) Annual Meeting and Exposition . For more than 60 years, the (ASH) Annual Meeting and Exposition has been the world’s most comprehensive hematology

MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.

… Thursday, November 14, 2019 Summary Despite many advances in diagnostic technologies, the original site of some cancers will never be found. A new tool may help. Experts estimate that between 2 and 5% of all cancers are classified as cancer of unknown primary (CUP) , also called occult primary cancer

The BRCA Founder Outreach study was recently launched to look at how patients undergo genetic screenings for cancer.

… Wednesday, April 25, 2018 Summary A new study led by MSK and three other cancer centers is looking at different aspects of testing for cancer genes. In March 2018, the US Food and Drug Administration approved an at-home, mail-in kit that tests for some of the inherited mutations in the genes BRCA1 and

Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou, China and New York on December 2, 2022.

… Wednesday, December 28, 2022 Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou